Actively Recruiting
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Led by SecuraBio · Updated on 2026-04-06
124
Participants Needed
44
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
CONDITIONS
Official Title
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed nodal T cell lymphoma with TFH phenotype according to WHO classification criteria including Angioimmunoblastic T cell lymphoma (AITL), follicular T cell lymphoma, and other nodal peripheral T cell lymphoma with TFH phenotype
- Relapsed or refractory to at least 1 prior systemic, cytotoxic therapy for T cell lymphoma
- Measurable disease as defined by Lugano 2014 criteria for T cell lymphoma
You will not qualify if you...
- Cutaneous-only disease
- Received prior allogeneic transplant any time in the past or autologous transplant within 60 days prior to first dose of study drug
- Received prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor
- Prior exposure to planned study treatment (gemcitabine or bendamustine) within 60 days prior to first dose of study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 44 locations
1
Universitair Ziekenhuis Gent (UZ Gent)
Ghent, Belgium, 9000
Actively Recruiting
2
UZ Leuven - Gasthuisberg Campus
Leuven, Belgium, 3000
Actively Recruiting
3
Vseobecna fakultni nemocnice
Prague, Czechia, 128 08
Actively Recruiting
4
Aarhus University Hospital
Aarhus, Denmark, DK-8200
Actively Recruiting
5
Rigshospitalet Copenhagen
Copenhagen, Denmark, DK-2100
Actively Recruiting
6
Odense Hospital
Odense, Denmark, DK-5000
Actively Recruiting
7
UNICANCER - Centre Henri-Becquerel
Rouen, Normandy, France, 76038 Cedex 1
Actively Recruiting
8
Institut Gustave Roussy
Villejuif, Vaillant, France, 94805
Actively Recruiting
9
CHU Cote de Nacre
Caen, France, 14033
Actively Recruiting
10
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63000
Actively Recruiting
11
CHU Montpellier
Montpellier, France, 34295
Actively Recruiting
12
CHU Nantes
Nantes, France, 44093
Actively Recruiting
13
Hopital Pitie Salpetriere
Paris, France, 75019
Actively Recruiting
14
CHU Bordeaux
Pessac, France, 33604
Actively Recruiting
15
Centre Hospitalier Lyon Sud
Pierre-Bénite, France, 69310
Actively Recruiting
16
CHU PONTCHAILLOU-Haematology
Rennes, France
Actively Recruiting
17
Institut Curie Paris
Saint-Cloud, France, 92210
Actively Recruiting
18
Evangelisches Krankenhaus Essen-Werden
Essen, Germany, 45239
Actively Recruiting
19
Universitaetsmedizin Goettingen (UMG) - Klinik fuer Haematologie und Medizinische Onkologie
Goettigen, Germany, 37075
Actively Recruiting
20
Universitaetsklinikum Halle (Saale)
Halle, Germany, 06120
Actively Recruiting
21
Universitaetsklinikum Leipzig- Klinik und Poliklinik fuer Haematologie und Zelltherapie
Leipzig, Germany, 04103
Actively Recruiting
22
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo - Alessandria
Alessandria, Italy, 15121
Actively Recruiting
23
Asst Papa Giovanni Xxiii Uo Ematologia
Bergamo, Italy, 24127
Actively Recruiting
24
Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
25
Ematologia Oncologia Instituto Pascale
Naples, Italy
Actively Recruiting
26
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy, 00168
Actively Recruiting
27
Amsterdam UMC location AMC
Amsterdam, Netherlands, 1105 AZ
Actively Recruiting
28
Leiden University Medical Center (LUMC)
Leiden, Netherlands, 2333 ZA
Actively Recruiting
29
Erasmus University Medical Center
Rotterdam, Netherlands, 3015GD
Actively Recruiting
30
Uniwersyteckie Centrum Kliniczne Oddzial Hematologii i Transplantologii
Gdansk, Poland, 80-214
Actively Recruiting
31
Pratia Centrum Medyczne Krakow
Krakow, Poland, 30-727
Actively Recruiting
32
Instytut Hematologii i Transfuzjologii
Warsaw, Poland, 02-776
Actively Recruiting
33
Narodowy Instytut Onkologii im. Marii Skłodowskiej - Curie
Warsaw, Poland, 02-781
Actively Recruiting
34
ICO Hospitalet (Hospital Duran i Reynals)
Barcelona, Spain, 08908
Actively Recruiting
35
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain, 37007
Actively Recruiting
36
Hospital Clinico Universitario de Salamanca
Salamanca, Spain, 58182
Actively Recruiting
37
Hospital Universitario Virgen del Rocio
Seville, Spain
Actively Recruiting
38
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT
Actively Recruiting
39
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
Actively Recruiting
40
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom, LE1 5WW
Actively Recruiting
41
UCLH NHS Foundation Trust
London, United Kingdom, NW1 2PG
Actively Recruiting
42
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Actively Recruiting
43
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG5 1PB
Actively Recruiting
44
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
Research Team
O
Ohad Bentur
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here